Bristol-Myers Squibb Company vs Merck & Company, Inc. — Stock Comparison
Bristol-Myers Squibb Company (BMY) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Merck & Company, Inc. narrowly edges Bristol-Myers Squibb Company on Q·Score (6.9 vs 6.6 out of 10), led by Sentiment (7.1 vs 5.2) and Health (7 vs 5.5). Bristol-Myers Squibb Company scores higher on Quality, reflecting stronger profitability and returns. Analyst price targets imply similar upside for both: +5.9% for BMY and +6.0% for MRK.
Q·Score Breakdown
High-quality business with 39% return on equity and 15% profit margins.
⚠ cautious analyst consensus — few Buy ratings.
High-quality business with 19% return on equity and 14% profit margins.
Analyst Consensus
Fundamentals
Frequently Asked Questions
BMY vs MRK: which stock scores better overall?
Based on Q·Score, Merck & Company, Inc. (MRK) scores 6.9/10 versus Bristol-Myers Squibb Company (BMY) at 6.6/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: BMY or MRK?
Merck & Company, Inc. (MRK) scores higher on Growth (6.2/10 vs 5.8/10). Bristol-Myers Squibb Company reports revenue growth (2.6% YoY) while Merck & Company, Inc. reports (4.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is BMY or MRK more attractively valued?
Bristol-Myers Squibb Company (BMY) scores higher on Valuation (6.4/10 vs 6.4/10). BMY trades at 9.6× P/E versus MRK at 12.9×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about BMY vs MRK?
There are 25 analysts covering BMY with a consensus price target of $62.96, and 27 analysts covering MRK with a consensus target of $129.74. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: BMY or MRK?
Bristol-Myers Squibb Company (BMY) scores higher on Quality (9.2/10 vs 7.7/10). Net profit margin: BMY at 15.0%, MRK at 13.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: BMY or MRK?
Merck & Company, Inc. (MRK) scores higher on Financial Health (7/10 vs 5.5/10). Market beta: BMY at 0.26, MRK at 0.20. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of BMY and MRK?
Bristol-Myers Squibb Company (BMY) has a market capitalisation of $121.4B, while Merck & Company, Inc. (MRK) has a market cap of $302.3B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do BMY or MRK pay dividends?
BMY pays a dividend yield of 4.24%, while MRK pays a dividend yield of 2.78%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →